首页 > 最新文献

Clinical & Translational Oncology最新文献

英文 中文
Establishment of matched bladder cancer PDX and PDX-derived organoid model and evaluation of anti-tumor efficacy of abemaciclib. 建立匹配的膀胱癌 PDX 和 PDX 衍生类器官模型并评估阿巴西利(abemaciclib)的抗肿瘤疗效。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-22 DOI: 10.1007/s12094-024-03666-3
Xiongbing Lu, Chao Hu, Lingxing Duan, Ke Chen, Hua Hao, Yuanqiao He

Introduction: Bladder cancer is one of the most common malignancies of the urinary system and there's a significant unmet need for new effective therapeutics for bladder cancer. The limited number of available models to study malignant bladder tumors is one of the obstructions in developing bladder cancer therapeutics. Patient-derived xenograft (PDX) and organoid (PDO) models are more representatives of human cancer than cell lines and cell line-derived xenograft (CDX) and are likely to be more promising and efficient in predicting drug response and finding new therapeutics.

Methods: Three pairs of patient-derived xenograft (PDX) models of bladder cancer and their corresponding PDX-derived organoids (PDXOs) were successfully established. These models were utilized to assess the efficacy of abemaciclib. The sensitivity of the drug was determined through the Cell Counting Kit-8 (CCK8) assay in PDXO cultures, corroborated by the EdU incorporation assay. Additionally, the in vivo tumor growth was monitored in the matched PDX models.

Results: In vitro PDXO cultures and in vivo PDX tumor models consistently demonstrated that abemaciclib had varying degrees of inhibitory effects across different bladder cancer (BC) patients. Notably, our study further revealed that treatment with abemaciclib significantly modified the expression patterns of CyclinD1/CDK4. This was achieved by not only diminishing their expression levels but also by shifting their expression from a membrane-associated localization to the nucleus.

Conclusion: Our research provided compelling evidence attesting to the reliability and potential of PDX and PDXO models in the realm of precision medicine. These models are instrumental in identifying patients who are likely to respond favorably to a specific drug treatment.

简介:膀胱癌是泌尿系统最常见的恶性肿瘤之一:膀胱癌是泌尿系统最常见的恶性肿瘤之一,目前对膀胱癌有效新疗法的需求尚未得到满足。可用来研究恶性膀胱肿瘤的模型数量有限,这是开发膀胱癌疗法的障碍之一。与细胞系和细胞系衍生异种移植(CDX)相比,患者衍生异种移植(PDX)和类器官(PDO)模型更能代表人类癌症,在预测药物反应和寻找新疗法方面可能更有前景和更有效率:方法: 成功建立了三对膀胱癌患者衍生异种移植物(PDX)模型及其相应的PDX衍生器官组织(PDXOs)。这些模型用于评估阿巴西利(abemaciclib)的疗效。在PDXO培养物中通过细胞计数试剂盒-8(CCK8)检测确定了药物的敏感性,并通过EdU掺入检测证实了这一点。此外,还对匹配的 PDX 模型进行了体内肿瘤生长监测:结果:体外 PDXO 培养物和体内 PDX 肿瘤模型一致表明,阿巴西利对不同的膀胱癌(BC)患者有不同程度的抑制作用。值得注意的是,我们的研究进一步揭示,阿柏西尼能显著改变CyclinD1/CDK4的表达模式。这不仅是通过降低它们的表达水平实现的,也是通过将它们的表达从膜相关定位转移到细胞核实现的:我们的研究提供了令人信服的证据,证明了 PDX 和 PDXO 模型在精准医疗领域的可靠性和潜力。这些模型有助于确定可能对特定药物治疗产生良好反应的患者。
{"title":"Establishment of matched bladder cancer PDX and PDX-derived organoid model and evaluation of anti-tumor efficacy of abemaciclib.","authors":"Xiongbing Lu, Chao Hu, Lingxing Duan, Ke Chen, Hua Hao, Yuanqiao He","doi":"10.1007/s12094-024-03666-3","DOIUrl":"https://doi.org/10.1007/s12094-024-03666-3","url":null,"abstract":"<p><strong>Introduction: </strong>Bladder cancer is one of the most common malignancies of the urinary system and there's a significant unmet need for new effective therapeutics for bladder cancer. The limited number of available models to study malignant bladder tumors is one of the obstructions in developing bladder cancer therapeutics. Patient-derived xenograft (PDX) and organoid (PDO) models are more representatives of human cancer than cell lines and cell line-derived xenograft (CDX) and are likely to be more promising and efficient in predicting drug response and finding new therapeutics.</p><p><strong>Methods: </strong>Three pairs of patient-derived xenograft (PDX) models of bladder cancer and their corresponding PDX-derived organoids (PDXOs) were successfully established. These models were utilized to assess the efficacy of abemaciclib. The sensitivity of the drug was determined through the Cell Counting Kit-8 (CCK8) assay in PDXO cultures, corroborated by the EdU incorporation assay. Additionally, the in vivo tumor growth was monitored in the matched PDX models.</p><p><strong>Results: </strong>In vitro PDXO cultures and in vivo PDX tumor models consistently demonstrated that abemaciclib had varying degrees of inhibitory effects across different bladder cancer (BC) patients. Notably, our study further revealed that treatment with abemaciclib significantly modified the expression patterns of CyclinD1/CDK4. This was achieved by not only diminishing their expression levels but also by shifting their expression from a membrane-associated localization to the nucleus.</p><p><strong>Conclusion: </strong>Our research provided compelling evidence attesting to the reliability and potential of PDX and PDXO models in the realm of precision medicine. These models are instrumental in identifying patients who are likely to respond favorably to a specific drug treatment.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synergistic effects of combined hyperthermia and electric fields treatment in non-small cell lung-cancer (NSCLC) cell lines. 在非小细胞肺癌(NSCLC)细胞系中联合使用热疗和电场治疗的协同效应。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-22 DOI: 10.1007/s12094-024-03760-6
Jinju Heo, Yunhui Jo, Myonggeun Yoon

Purpose: Lung cancer remains a leading cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) being particularly challenging due to poor survival rates, emphasizing the need for new treatments. This study examined the therapeutic effects of combining hyperthermia (HT) with tumor-treating electric fields (TTF) in NSCLC.

Methods: Cells were exposed to four different conditions: hyperthermia at 42 °C for 30 min, electric fields at 150 kHz and 0.8 V/cm for 24 h, a combination of both treatments, or no treatment (control). Cell proliferation was measured using WST and colony-formation assays, while apoptosis, DNA damage, and repair protein levels were analyzed via Western blotting. Metastatic potential was evaluated with a transwell assay, and cell migration was assessed using the wound-healing assay.

Results: The combination therapy significantly inhibited colony formation and reduced cell migration and invasion more effectively than individual treatments. The combined treatment also enhanced apoptosis, as indicated by increased cleaved-PARP and Annexin V levels. In addition, the DNA-damage marker γ-H2AX was elevated, while BRCA1, a protein involved in DNA repair, was significantly downregulated compared to the individual treatments.

Conclusions: These results suggest that the enhanced anticancer effects of HT and TTF are due to increased DNA damage and suppression of DNA-repair mechanisms, highlighting the potential of this combination therapy for NSCLC treatment.

目的:肺癌仍然是癌症相关死亡的主要原因,其中非小细胞肺癌(NSCLC)因存活率低而尤其具有挑战性,强调了对新疗法的需求。本研究探讨了热疗(HT)与肿瘤治疗电场(TTF)相结合对 NSCLC 的治疗效果:细胞暴露于四种不同的条件下:42 ℃热疗 30 分钟、150 kHz 和 0.8 V/cm 的电场 24 小时、两种治疗的组合或无治疗(对照组)。细胞增殖采用 WST 和集落形成试验进行测定,细胞凋亡、DNA 损伤和修复蛋白水平则通过 Western 印迹进行分析。转移潜能通过跨孔试验进行评估,细胞迁移通过伤口愈合试验进行评估:结果:与单独治疗相比,联合疗法能更有效地抑制集落形成,减少细胞迁移和侵袭。联合疗法还能增强细胞凋亡,表现为裂解-PARP 和 Annexin V 水平的升高。此外,DNA损伤标记物γ-H2AX升高,而参与DNA修复的蛋白质BRCA1与单独治疗相比显著下调:这些结果表明,HT和TTF增强抗癌效果的原因是DNA损伤增加和DNA修复机制受到抑制,这凸显了这种联合疗法治疗NSCLC的潜力。
{"title":"Synergistic effects of combined hyperthermia and electric fields treatment in non-small cell lung-cancer (NSCLC) cell lines.","authors":"Jinju Heo, Yunhui Jo, Myonggeun Yoon","doi":"10.1007/s12094-024-03760-6","DOIUrl":"https://doi.org/10.1007/s12094-024-03760-6","url":null,"abstract":"<p><strong>Purpose: </strong>Lung cancer remains a leading cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) being particularly challenging due to poor survival rates, emphasizing the need for new treatments. This study examined the therapeutic effects of combining hyperthermia (HT) with tumor-treating electric fields (TTF) in NSCLC.</p><p><strong>Methods: </strong>Cells were exposed to four different conditions: hyperthermia at 42 °C for 30 min, electric fields at 150 kHz and 0.8 V/cm for 24 h, a combination of both treatments, or no treatment (control). Cell proliferation was measured using WST and colony-formation assays, while apoptosis, DNA damage, and repair protein levels were analyzed via Western blotting. Metastatic potential was evaluated with a transwell assay, and cell migration was assessed using the wound-healing assay.</p><p><strong>Results: </strong>The combination therapy significantly inhibited colony formation and reduced cell migration and invasion more effectively than individual treatments. The combined treatment also enhanced apoptosis, as indicated by increased cleaved-PARP and Annexin V levels. In addition, the DNA-damage marker γ-H2AX was elevated, while BRCA1, a protein involved in DNA repair, was significantly downregulated compared to the individual treatments.</p><p><strong>Conclusions: </strong>These results suggest that the enhanced anticancer effects of HT and TTF are due to increased DNA damage and suppression of DNA-repair mechanisms, highlighting the potential of this combination therapy for NSCLC treatment.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer cell-extrinsic STING shapes immune-active microenvironment and predicts clinical outcome in gastric cancer. 癌细胞外源性 STING 塑造免疫活性微环境并预测胃癌的临床预后
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-16 DOI: 10.1007/s12094-024-03726-8
Ye Wei, Quanguang Ren, Pengbo Hu, You Zou, Wei Yao, Hong Qiu

Purpose: The activation of cGAS-STING pathway can be triggered by cytosolic double-stranded DNA (dsDNA) in tumor and non-tumor compartments. We aim to assess the constitutive expression of dsDNA-cGAS-STING axis in different cellular contexts and compare their relative contribution to clinical outcomes.

Methods: A cohort of 154 cases of patients with newly diagnosed gastric cancer were enrolled in this study to evaluate the histo-score of cytosolic dsDNA, cGAS, and STING via immunohistochemistry as well as the types and densities of tumor-infiltrating immune cells. Kaplan-Meier method, multivariable regression, and receiver operating characteristic curve were implemented to analyze the prognostic efficacy of dsDNA-cGAS-STING axis in distinct compartments.

Results: The supra-normal concentration of cytosolic dsDNA correlated with the constitutive expression of cGAS-STING pathway in tumor compartments. In contrast to the lack of STING within cancer cells, the higher STING expression in non-tumor compartments indicated a transcellular cGAS-STING activation. Cancer cell-extrinsic STING was supported to potentiate nucleic acid immunity by sensing tumor-derived dsDNA fragments. Compartmental analyses also confirmed that the level of STING expressed in non-tumor cells was associated with the infiltration of protective immune cells, leading to the prolonged overall survival. Multivariate analysis further identified the independent prognostic value of cancer cell-extrinsic STING and its predictive accuracy could be significantly improved in combination with the immune cell infiltration.

Conclusions: Cancer cell-extrinsic STING facilitates the remodeling of immune-active tumor microenvironment and acts as an independent prognostic factor in gastric cancer.

目的:cGAS-STING通路的激活可由肿瘤和非肿瘤区室中的细胞膜双链DNA(dsDNA)触发。我们旨在评估dsDNA-cGAS-STING轴在不同细胞环境中的组成性表达,并比较它们对临床结果的相对贡献:方法:本研究共纳入 154 例新诊断胃癌患者,通过免疫组化方法评估细胞膜 dsDNA、cGAS 和 STING 的组织评分,以及肿瘤浸润免疫细胞的类型和密度。采用卡普兰-梅耶法、多变量回归法和接收者操作特征曲线分析dsDNA-cGAS-STING轴在不同分区的预后效果:结果:细胞膜dsDNA的超常浓度与肿瘤分区中cGAS-STING通路的构成性表达相关。与癌细胞内缺乏 STING 相反,非肿瘤区块中 STING 的表达较高,表明 cGAS-STING 激活了跨细胞。癌细胞外STING通过感知肿瘤衍生的dsDNA片段来增强核酸免疫。区组分析还证实,非肿瘤细胞中表达的STING水平与保护性免疫细胞的浸润有关,从而导致总生存期的延长。多变量分析进一步确定了癌细胞外STING的独立预后价值,其预测准确性与免疫细胞浸润相结合可显著提高:结论:癌细胞外STING促进了免疫活性肿瘤微环境的重塑,是胃癌的一个独立预后因素。
{"title":"Cancer cell-extrinsic STING shapes immune-active microenvironment and predicts clinical outcome in gastric cancer.","authors":"Ye Wei, Quanguang Ren, Pengbo Hu, You Zou, Wei Yao, Hong Qiu","doi":"10.1007/s12094-024-03726-8","DOIUrl":"https://doi.org/10.1007/s12094-024-03726-8","url":null,"abstract":"<p><strong>Purpose: </strong>The activation of cGAS-STING pathway can be triggered by cytosolic double-stranded DNA (dsDNA) in tumor and non-tumor compartments. We aim to assess the constitutive expression of dsDNA-cGAS-STING axis in different cellular contexts and compare their relative contribution to clinical outcomes.</p><p><strong>Methods: </strong>A cohort of 154 cases of patients with newly diagnosed gastric cancer were enrolled in this study to evaluate the histo-score of cytosolic dsDNA, cGAS, and STING via immunohistochemistry as well as the types and densities of tumor-infiltrating immune cells. Kaplan-Meier method, multivariable regression, and receiver operating characteristic curve were implemented to analyze the prognostic efficacy of dsDNA-cGAS-STING axis in distinct compartments.</p><p><strong>Results: </strong>The supra-normal concentration of cytosolic dsDNA correlated with the constitutive expression of cGAS-STING pathway in tumor compartments. In contrast to the lack of STING within cancer cells, the higher STING expression in non-tumor compartments indicated a transcellular cGAS-STING activation. Cancer cell-extrinsic STING was supported to potentiate nucleic acid immunity by sensing tumor-derived dsDNA fragments. Compartmental analyses also confirmed that the level of STING expressed in non-tumor cells was associated with the infiltration of protective immune cells, leading to the prolonged overall survival. Multivariate analysis further identified the independent prognostic value of cancer cell-extrinsic STING and its predictive accuracy could be significantly improved in combination with the immune cell infiltration.</p><p><strong>Conclusions: </strong>Cancer cell-extrinsic STING facilitates the remodeling of immune-active tumor microenvironment and acts as an independent prognostic factor in gastric cancer.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pyrimidine metabolism reshapes immune microenvironment and implies poor prognosis in glioma. 嘧啶代谢重塑免疫微环境,意味着胶质瘤预后不良。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-16 DOI: 10.1007/s12094-024-03753-5
Ruoyu Huang, Jingchen Yang, Xuejing Li, Huiyuan Chen, Xing Liu

Background: The metabolic environment of glioma is extremely complex. Pyrimidine metabolism can significantly influence malignant progression of multiple kinds of cancer cells. In this study, we intend to explore the relationship between pyrimidine metabolism and malignant progression of glioma.

Methods: We analyzed two glioma RNA-sequencing databases to construct a pyrimidine metabolism-related risk signature. An individualized prognosis prediction model based on this risk signature was established. Functional analysis and in vitro experiments were conducted to assess the role of pyrimidine metabolism in the tumor-immune microenvironment and malignant progress of gliomas.

Results: The high-risk group, as predicted by the pyrimidine metabolism-related risk score, showed a tendency toward more malignant entities and poorer survival outcomes. Functional analysis revealed that pyrimidine metabolism significantly regulates the tumor-immune microenvironment. In vitro experiments confirmed that targeting pyrimidine metabolism-related genes can inhibit malignancy of glioma cell.

Conclusion: In short, the pyrimidine metabolism-related signature we established could serve as an independent prognostic biomarker in diffuse gliomas and has a close association with regulation of the tumor-immune microenvironment.

背景:胶质瘤的代谢环境极其复杂。嘧啶代谢可显著影响多种癌细胞的恶性进展。本研究旨在探讨嘧啶代谢与胶质瘤恶性进展之间的关系:方法:我们分析了两个胶质瘤 RNA 序列数据库,构建了嘧啶代谢相关风险特征。方法:我们分析了两个胶质瘤 RNA 序列数据库,构建了一个嘧啶代谢相关风险特征,并基于该风险特征建立了一个个体化预后预测模型。通过功能分析和体外实验评估了嘧啶代谢在肿瘤免疫微环境和胶质瘤恶性进展中的作用:结果:根据嘧啶代谢相关风险评分预测,高危组有恶性程度更高、生存率更低的趋势。功能分析显示,嘧啶代谢对肿瘤免疫微环境有显著调节作用。体外实验证实,靶向嘧啶代谢相关基因可抑制胶质瘤细胞的恶性程度:总之,我们建立的嘧啶代谢相关特征可作为弥漫性胶质瘤的独立预后生物标志物,并与肿瘤免疫微环境调控密切相关。
{"title":"Pyrimidine metabolism reshapes immune microenvironment and implies poor prognosis in glioma.","authors":"Ruoyu Huang, Jingchen Yang, Xuejing Li, Huiyuan Chen, Xing Liu","doi":"10.1007/s12094-024-03753-5","DOIUrl":"https://doi.org/10.1007/s12094-024-03753-5","url":null,"abstract":"<p><strong>Background: </strong>The metabolic environment of glioma is extremely complex. Pyrimidine metabolism can significantly influence malignant progression of multiple kinds of cancer cells. In this study, we intend to explore the relationship between pyrimidine metabolism and malignant progression of glioma.</p><p><strong>Methods: </strong>We analyzed two glioma RNA-sequencing databases to construct a pyrimidine metabolism-related risk signature. An individualized prognosis prediction model based on this risk signature was established. Functional analysis and in vitro experiments were conducted to assess the role of pyrimidine metabolism in the tumor-immune microenvironment and malignant progress of gliomas.</p><p><strong>Results: </strong>The high-risk group, as predicted by the pyrimidine metabolism-related risk score, showed a tendency toward more malignant entities and poorer survival outcomes. Functional analysis revealed that pyrimidine metabolism significantly regulates the tumor-immune microenvironment. In vitro experiments confirmed that targeting pyrimidine metabolism-related genes can inhibit malignancy of glioma cell.</p><p><strong>Conclusion: </strong>In short, the pyrimidine metabolism-related signature we established could serve as an independent prognostic biomarker in diffuse gliomas and has a close association with regulation of the tumor-immune microenvironment.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pemetrexed and platinum with or without pembrolizumab for advanced non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis. 培美曲塞和铂类联合或不联合培美单抗治疗晚期非小细胞肺癌(NSCLC):系统综述和荟萃分析。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-15 DOI: 10.1007/s12094-024-03751-7
Zichen Zhao, Chuchu Yang, Jiashu Li

Objective: This meta-analysis aimed to evaluate the efficacy and safety of combining pemetrexed and platinum with or without pembrolizumab for the treatment of advanced non-small-cell lung cancer (NSCLC).

Methods: A systematic search of PubMed, Embase, Cochrane Library, and Web Of Science databases was conducted to identify studies comparing pemetrexed and platinum with or without pembrolizumab in advanced NSCLC. Raw data were extracted from eligible studies to calculate Hazard Ratios (HR) for Progression-Free Survival (PFS) and Overall Survival (OS), as well as rates of adverse events of all grades and those of Grade 3 or higher.

Results: Eight studies with 1639 patients occurred advanced NSCLC included. The group receiving pembrolizumab in combination with pemetrexed and platinum showed significant benefits in terms of OS (HR 0.63; 95% CI 0.54-0.73; p < 0.00001) and PFS (HR:0.64; 95% CI 0.48-0.85; p = 0.002) compared to the group receiving pemetrexed and platinum alone. However, this benefit was accompanied by a higher incidence of Grade 3 or higher adverse events (OR: 1.55; 95% CI 1.24-1.95; p = 0.0001).

Conclusion: The combination of pemetrexed and platinum with pembrolizumab is recommended as a first-line treatment option for advanced NSCLC due to its significant efficacy benefits. However, the increased risk of Grade 3 or higher adverse events suggests the need for careful consideration and assessment when considering this regimen for second-line or subsequent therapy.

研究目的这项荟萃分析旨在评估培美曲塞和铂联合或不联合使用彭博拉珠单抗治疗晚期非小细胞肺癌(NSCLC)的有效性和安全性:对PubMed、Embase、Cochrane Library和Web Of Science数据库进行了系统检索,以确定在晚期NSCLC中比较培美曲塞和铂联合或不联合培美曲塞的研究。从符合条件的研究中提取原始数据,计算无进展生存期(PFS)和总生存期(OS)的危险比(HR),以及所有等级和3级或以上不良事件的发生率:八项研究共纳入了1639名晚期NSCLC患者。由于培美曲塞和铂联合使用pembrolizumab具有显著疗效,因此推荐将其作为晚期NSCLC的一线治疗方案。然而,3级或更高不良事件风险的增加表明,在考虑将该方案用于二线或后续治疗时,需要慎重考虑和评估。
{"title":"Pemetrexed and platinum with or without pembrolizumab for advanced non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis.","authors":"Zichen Zhao, Chuchu Yang, Jiashu Li","doi":"10.1007/s12094-024-03751-7","DOIUrl":"https://doi.org/10.1007/s12094-024-03751-7","url":null,"abstract":"<p><strong>Objective: </strong>This meta-analysis aimed to evaluate the efficacy and safety of combining pemetrexed and platinum with or without pembrolizumab for the treatment of advanced non-small-cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>A systematic search of PubMed, Embase, Cochrane Library, and Web Of Science databases was conducted to identify studies comparing pemetrexed and platinum with or without pembrolizumab in advanced NSCLC. Raw data were extracted from eligible studies to calculate Hazard Ratios (HR) for Progression-Free Survival (PFS) and Overall Survival (OS), as well as rates of adverse events of all grades and those of Grade 3 or higher.</p><p><strong>Results: </strong>Eight studies with 1639 patients occurred advanced NSCLC included. The group receiving pembrolizumab in combination with pemetrexed and platinum showed significant benefits in terms of OS (HR 0.63; 95% CI 0.54-0.73; p < 0.00001) and PFS (HR:0.64; 95% CI 0.48-0.85; p = 0.002) compared to the group receiving pemetrexed and platinum alone. However, this benefit was accompanied by a higher incidence of Grade 3 or higher adverse events (OR: 1.55; 95% CI 1.24-1.95; p = 0.0001).</p><p><strong>Conclusion: </strong>The combination of pemetrexed and platinum with pembrolizumab is recommended as a first-line treatment option for advanced NSCLC due to its significant efficacy benefits. However, the increased risk of Grade 3 or higher adverse events suggests the need for careful consideration and assessment when considering this regimen for second-line or subsequent therapy.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Harnessing hematological ratios: prognostic insights for breast cancer management. 利用血液学比率:对乳腺癌预后管理的启示。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-14 DOI: 10.1007/s12094-024-03721-z
Carolina Coradi, Carolina Panis

Background: Breast cancer is one of the most lethal diseases affecting women globally. Its progression is influenced by various factors, including the immune system's ability to combat cancer cells. While hematological indices have been recognized as valuable biomarkers for monitoring patients with different types of neoplasms, there remains a considerable gap in research concerning their application in breast cancer.

Material and methods: To address this, we conducted a systematic review of studies examining hematological indices as prognostic predictors in breast cancer patients.

Results: The majority of studies demonstrate a significant correlation between these indices and survival outcomes, underscoring their potential utility in patient monitoring.

Conclusions: Hematological-based indexes can be valuable tools for monitoring breast cancer, especially those ongoing poor prognosis scenarios.

背景:乳腺癌是影响全球妇女的最致命疾病之一。其进展受多种因素影响,包括免疫系统对抗癌细胞的能力。虽然血液学指标已被认为是监测不同类型肿瘤患者的重要生物标志物,但有关其在乳腺癌中应用的研究仍存在相当大的差距:为了解决这个问题,我们对将血液学指标作为乳腺癌患者预后预测指标的研究进行了系统回顾:结果:大多数研究表明,这些指数与生存结果之间存在明显的相关性,凸显了它们在患者监测中的潜在作用:结论:基于血液学的指数是监测乳腺癌的重要工具,尤其是那些预后较差的患者。
{"title":"Harnessing hematological ratios: prognostic insights for breast cancer management.","authors":"Carolina Coradi, Carolina Panis","doi":"10.1007/s12094-024-03721-z","DOIUrl":"https://doi.org/10.1007/s12094-024-03721-z","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is one of the most lethal diseases affecting women globally. Its progression is influenced by various factors, including the immune system's ability to combat cancer cells. While hematological indices have been recognized as valuable biomarkers for monitoring patients with different types of neoplasms, there remains a considerable gap in research concerning their application in breast cancer.</p><p><strong>Material and methods: </strong>To address this, we conducted a systematic review of studies examining hematological indices as prognostic predictors in breast cancer patients.</p><p><strong>Results: </strong>The majority of studies demonstrate a significant correlation between these indices and survival outcomes, underscoring their potential utility in patient monitoring.</p><p><strong>Conclusions: </strong>Hematological-based indexes can be valuable tools for monitoring breast cancer, especially those ongoing poor prognosis scenarios.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combining serum CDK1 with tumor markers for the diagnosis of small cell lung cancer. 结合血清 CDK1 和肿瘤标志物诊断小细胞肺癌。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-13 DOI: 10.1007/s12094-024-03722-y
Kexin Han, Yinyi Chen, Xinlu Sun, Lili Wen, Yang Wu, Simei Chen, Liping Wei, Jianlin Yu, Tingting Zeng, Lei Jiang, Liming Tan

Objective: An investigation of the diagnostic and clinical value of cell cycle-dependent kinase 1 (CDK1) in small cell lung cancer (SCLC).

Methods: A large tertiary hospital in Jiangxi Province enrolled 80 SCLC cases, 105 cases of non-small cell lung cancer (NSCLC), 114 cases of pulmonary nodule (PN) and 60 control cases from December 2022 to December 2023. ELISA was used to measure CDK1 levels in serum. The expression levers of neuron-specific enolase (NSE), Pro gastrin-releasing peptide (ProGRP), squamous cell carcinoma antigen (SCCA), carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199) and cytokeratin 19 fragment (YFRA21-1) were detected by electrochemiluminescence immunoassay.

Results: ①CDK1, ProGRP, NSE, and CA199 expressions were significantly higher in the SCLC group compared to the NSCLC, PN and Control groups (P < 0.01). ②Spearman correlation analysis showed that serum levels of CDK1, NSE, and ProGRP were associated with clinical staging and lymph node metastasis in SCLC patients (P < 0.05). ③The serum levels of CDK1, NSE, and ProGRP in patients with extensive-disease (ED) SCLC were higher than those in patients with limited-disease (LD) SCLC (P < 0.05), and the serum levels of CDK1, NSE, and ProGRP in SCLC patients with lymph node metastasis were higher than those without lymph node metastasis (P < 0.05). ④Compared with the NSCLC group, the AUC of subjects diagnosed with SCLC by CDK1 was the largest and the sensitivity was the highest, 0.831 and 72.50%, the specificity of ProGRP in diagnosing SCLC is the highest, at 95.20% (P < 0.01). Compared with the PN group, CDK1 had the highest AUC, sensitivity, and specificity in diagnosing SCLC, with values of 0.93%, 88.80%, and 94.70%, respectively (P < 0.01). ⑤The combination of CDK1, ProGRP and NSE had the highest AUC and sensitivity of 0.903 and 86.30% for the diagnosis of SCLC (P < 0.01).

Conclusion: CDK1 not only plays an important role in assisting the diagnosis of SCLC but also in the differential diagnosis between SCLC and NSCLC. The combination of CDK1 and NSE and ProGRP can significantly improve the diagnostic performance and provide new ideas for the clinical diagnosis of SCLC.

目的研究细胞周期依赖性激酶1(CDK1)在小细胞肺癌(SCLC)中的诊断和临床价值:方法:江西省某大型三甲医院从2022年12月至2023年12月共收治小细胞肺癌(SCLC)病例80例、非小细胞肺癌(NSCLC)病例105例、肺结节(PN)病例114例和对照病例60例。采用酶联免疫吸附法测定血清中 CDK1 的水平。电化学发光免疫测定法检测神经元特异性烯醇化酶(NSE)、促胃泌素释放肽(ProGRP)、鳞状细胞癌抗原(SCCA)、癌胚抗原(CEA)、碳水化合物抗原199(CA199)和细胞角蛋白19片段(YFRA21-1)的表达水平:结果:①CDK1、ProGRP、NSE和CA199在SCLC组中的表达量明显高于NSCLC组、PN组和对照组(P 结论:CDK1不仅在肿瘤细胞中起着重要作用,而且在肿瘤细胞中也起着重要作用:CDK1 不仅在 SCLC 的辅助诊断中发挥着重要作用,而且在 SCLC 和 NSCLC 的鉴别诊断中也发挥着重要作用。CDK1与NSE和ProGRP的联合检测可显著提高诊断效果,为SCLC的临床诊断提供新思路。
{"title":"Combining serum CDK1 with tumor markers for the diagnosis of small cell lung cancer.","authors":"Kexin Han, Yinyi Chen, Xinlu Sun, Lili Wen, Yang Wu, Simei Chen, Liping Wei, Jianlin Yu, Tingting Zeng, Lei Jiang, Liming Tan","doi":"10.1007/s12094-024-03722-y","DOIUrl":"https://doi.org/10.1007/s12094-024-03722-y","url":null,"abstract":"<p><strong>Objective: </strong>An investigation of the diagnostic and clinical value of cell cycle-dependent kinase 1 (CDK1) in small cell lung cancer (SCLC).</p><p><strong>Methods: </strong>A large tertiary hospital in Jiangxi Province enrolled 80 SCLC cases, 105 cases of non-small cell lung cancer (NSCLC), 114 cases of pulmonary nodule (PN) and 60 control cases from December 2022 to December 2023. ELISA was used to measure CDK1 levels in serum. The expression levers of neuron-specific enolase (NSE), Pro gastrin-releasing peptide (ProGRP), squamous cell carcinoma antigen (SCCA), carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199) and cytokeratin 19 fragment (YFRA21-1) were detected by electrochemiluminescence immunoassay.</p><p><strong>Results: </strong>①CDK1, ProGRP, NSE, and CA199 expressions were significantly higher in the SCLC group compared to the NSCLC, PN and Control groups (P < 0.01). ②Spearman correlation analysis showed that serum levels of CDK1, NSE, and ProGRP were associated with clinical staging and lymph node metastasis in SCLC patients (P < 0.05). ③The serum levels of CDK1, NSE, and ProGRP in patients with extensive-disease (ED) SCLC were higher than those in patients with limited-disease (LD) SCLC (P < 0.05), and the serum levels of CDK1, NSE, and ProGRP in SCLC patients with lymph node metastasis were higher than those without lymph node metastasis (P < 0.05). ④Compared with the NSCLC group, the AUC of subjects diagnosed with SCLC by CDK1 was the largest and the sensitivity was the highest, 0.831 and 72.50%, the specificity of ProGRP in diagnosing SCLC is the highest, at 95.20% (P < 0.01). Compared with the PN group, CDK1 had the highest AUC, sensitivity, and specificity in diagnosing SCLC, with values of 0.93%, 88.80%, and 94.70%, respectively (P < 0.01). ⑤The combination of CDK1, ProGRP and NSE had the highest AUC and sensitivity of 0.903 and 86.30% for the diagnosis of SCLC (P < 0.01).</p><p><strong>Conclusion: </strong>CDK1 not only plays an important role in assisting the diagnosis of SCLC but also in the differential diagnosis between SCLC and NSCLC. The combination of CDK1 and NSE and ProGRP can significantly improve the diagnostic performance and provide new ideas for the clinical diagnosis of SCLC.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Salvage reirradiation for recurrent glioblastoma: a retrospective case series analysis. 复发性胶质母细胞瘤的挽救性再照射:回顾性病例系列分析。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-10 DOI: 10.1007/s12094-024-03750-8
Anna Lucas Calduch, Miquel Macià Garau, Salvador Villà Freixa, Nagore García Expósito, Ignasi Modolell Farré, Carles Majós Torró, Albert Pons Escoda, Carlos Mesía Barroso, Noelia Vilariño Quintela, Aleix Rosselló Gómez, Gerard Plans Ahicart, María Martínez García, Anna Esteve Gómez, Jordi Bruna Escuer

Purpose: To assess the clinical outcome of patients with recurrent glioblastoma treated with salvage reirradiation.

Methods: Between 2005 and 2022, data from adult patients with glioblastoma treated with surgery and radio-chemotherapy Stupp regimen who developed a local in-field relapse and received stereotactic radiotherapy (SRT) were retrospectively reviewed.

Results: The study population included 44 patients with recurrent glioblastoma (median of 9.5 months after the first radiotherapy). Reirradiation alone was given to 47.7% of patients. The median maximum diameter of the recurrence was 13.5 mm. The most common SRT regimen (52.3%) was 35 Gy in 10 fractions. Acute toxicity was mild, with transient worsening of previous neurological symptoms in only 15% of patients. After a median follow-up of 15 months, 40% presented radiological response, but a remarkable number of early distant progressions were recorded (32.5%). The median time to progression was 4.8 months, being the dose, the scheme, the size of the recurrence or the strategy (exclusive RT vs. combined) unrelated factors. The median overall survival (OS) was 14.9 months. Karnofsky index < 70 and the size of the recurrence (maximum diameter < 25 mm) were significant factors associated with OS. Radiological changes after reirradiation were commonly seen (> 50% of patients) hindering the response assessment.

Conclusions: Reirradiation is a feasible and safe therapeutic option to treat localized glioblastoma recurrences, able to control the disease for a few months in selected patients, especially those with good functional status and small lesions. Hypofractionated schemes provided a suitable toxicity profile. Radiological changes were common.

目的:评估接受挽救性再放射治疗的复发性胶质母细胞瘤患者的临床疗效:方法:回顾性研究2005年至2022年间接受手术和放射化疗Stupp方案治疗的成年胶质母细胞瘤患者的数据,这些患者出现了局部场内复发并接受了立体定向放射治疗(SRT):研究对象包括44名复发胶质母细胞瘤患者(首次放疗后的中位时间为9.5个月)。47.7%的患者接受了单纯再放疗。复发的中位最大直径为13.5毫米。最常见的 SRT 方案(52.3%)是 35 Gy,10 次分割。急性毒性较轻,仅有15%的患者之前的神经症状出现一过性恶化。在中位随访15个月后,40%的患者出现了放射学反应,但也记录了大量早期远处进展(32.5%)。中位进展时间为4.8个月,与剂量、方案、复发大小或策略(单纯RT与联合RT)无关。中位总生存期(OS)为14.9个月。结论:再照射是治疗局部胶质母细胞瘤复发的一种可行且安全的治疗方案,对于经过选择的患者,尤其是功能状况良好且病灶较小的患者,能在数月内控制病情。低分次方案具有适当的毒性。放射学改变很常见。
{"title":"Salvage reirradiation for recurrent glioblastoma: a retrospective case series analysis.","authors":"Anna Lucas Calduch, Miquel Macià Garau, Salvador Villà Freixa, Nagore García Expósito, Ignasi Modolell Farré, Carles Majós Torró, Albert Pons Escoda, Carlos Mesía Barroso, Noelia Vilariño Quintela, Aleix Rosselló Gómez, Gerard Plans Ahicart, María Martínez García, Anna Esteve Gómez, Jordi Bruna Escuer","doi":"10.1007/s12094-024-03750-8","DOIUrl":"https://doi.org/10.1007/s12094-024-03750-8","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the clinical outcome of patients with recurrent glioblastoma treated with salvage reirradiation.</p><p><strong>Methods: </strong>Between 2005 and 2022, data from adult patients with glioblastoma treated with surgery and radio-chemotherapy Stupp regimen who developed a local in-field relapse and received stereotactic radiotherapy (SRT) were retrospectively reviewed.</p><p><strong>Results: </strong>The study population included 44 patients with recurrent glioblastoma (median of 9.5 months after the first radiotherapy). Reirradiation alone was given to 47.7% of patients. The median maximum diameter of the recurrence was 13.5 mm. The most common SRT regimen (52.3%) was 35 Gy in 10 fractions. Acute toxicity was mild, with transient worsening of previous neurological symptoms in only 15% of patients. After a median follow-up of 15 months, 40% presented radiological response, but a remarkable number of early distant progressions were recorded (32.5%). The median time to progression was 4.8 months, being the dose, the scheme, the size of the recurrence or the strategy (exclusive RT vs. combined) unrelated factors. The median overall survival (OS) was 14.9 months. Karnofsky index < 70 and the size of the recurrence (maximum diameter < 25 mm) were significant factors associated with OS. Radiological changes after reirradiation were commonly seen (> 50% of patients) hindering the response assessment.</p><p><strong>Conclusions: </strong>Reirradiation is a feasible and safe therapeutic option to treat localized glioblastoma recurrences, able to control the disease for a few months in selected patients, especially those with good functional status and small lesions. Hypofractionated schemes provided a suitable toxicity profile. Radiological changes were common.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142401864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and validation of a relatively accurate gastric cancer high-risk group screening scoring system in urban residents. 在城市居民中开发和验证相对准确的胃癌高危人群筛查评分系统。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-08 DOI: 10.1007/s12094-024-03748-2
Weipeng Zhao, Tian Li, Ping Wang, Rui Zhang, Fan Gao, Zongfeng Ma, Siqi Zhen, Feng Liu, Yanliu Chu

Purpose: Our study aimed to develop a relatively accurate gastric cancer (GC) screening score system for urban residents and to validate the screening efficacy.

Methods: The present study included a derivation cohort (n = 3406) and a validation cohort (n = 868) of urban residents. Applying the full-stack engineering intelligent system platform of Hualian Health Big Data of Shandong University, the clinical physical examination data of subjects were collected. Univariate and multivariate analyses were used to identify risk factors for GC, and subsequently, an optimal prediction rule was established to create three distinct scoring systems.

Results: In the GC-risk scoring system I, age, plateletocrit (PCT), carcinoembryonic antigen (CEA), glucose, albumin, creatinine were independent risk factors of GC, with scores ranging from 0 to 28 and optimal cut-off was 15.5. The second scoring system consisted of age, PCT, RDW-CV, CEA, glucose, albumin, and creatinine, with scores ranging from 0 to 31. The optimal cut-off point was determined to be 15.5. The scoring system III comprise of age, sex, PCT, RDW CV, CEA, glucose, with scores ranging from 0 to 21 and optimal cut-off was 10.5. All three scoring systems demonstrated excellent discrimination for GC, achieving an AUC of 0.884, 0.89, and 0.876, respectively. In external validation, the AUC values were 0.654, 0.658, and 0.714. Notably, the GC-risk scoring system III exhibited the highest screening efficiency.

Conclusions: Urban residents benefited from the effective and verified GC-risk scoring systems, which demonstrated excellent performance in identifying individuals with an elevated risk of GC.

目的:我们的研究旨在为城市居民开发一个相对准确的胃癌(GC)筛查评分系统,并验证其筛查效果:方法:本研究包括城市居民衍生队列(3406 人)和验证队列(868 人)。应用山东大学华联健康大数据全栈工程智能系统平台,收集受试者的临床体检数据。采用单变量和多变量分析确定 GC 的风险因素,并建立最佳预测规则,形成三个不同的评分系统:在 GC 风险评分系统 I 中,年龄、血小板比容 (PCT)、癌胚抗原 (CEA)、血糖、白蛋白、肌酐是 GC 的独立风险因素,评分范围为 0 至 28 分,最佳临界值为 15.5。第二个评分系统由年龄、PCT、RDW-CV、CEA、葡萄糖、白蛋白和肌酐组成,评分范围为 0 至 31 分。最佳截断点被确定为 15.5。评分系统 III 包括年龄、性别、PCT、RDW-CV、CEA、葡萄糖,评分范围为 0 至 21 分,最佳临界点为 10.5。这三种评分系统对 GC 都有很好的区分度,AUC 分别为 0.884、0.89 和 0.876。在外部验证中,AUC 值分别为 0.654、0.658 和 0.714。值得注意的是,GC-风险评分系统 III 的筛查效率最高:城市居民受益于有效且经过验证的 GC 风险评分系统,该系统在识别 GC 风险升高的个体方面表现出色。
{"title":"Development and validation of a relatively accurate gastric cancer high-risk group screening scoring system in urban residents.","authors":"Weipeng Zhao, Tian Li, Ping Wang, Rui Zhang, Fan Gao, Zongfeng Ma, Siqi Zhen, Feng Liu, Yanliu Chu","doi":"10.1007/s12094-024-03748-2","DOIUrl":"https://doi.org/10.1007/s12094-024-03748-2","url":null,"abstract":"<p><strong>Purpose: </strong>Our study aimed to develop a relatively accurate gastric cancer (GC) screening score system for urban residents and to validate the screening efficacy.</p><p><strong>Methods: </strong>The present study included a derivation cohort (n = 3406) and a validation cohort (n = 868) of urban residents. Applying the full-stack engineering intelligent system platform of Hualian Health Big Data of Shandong University, the clinical physical examination data of subjects were collected. Univariate and multivariate analyses were used to identify risk factors for GC, and subsequently, an optimal prediction rule was established to create three distinct scoring systems.</p><p><strong>Results: </strong>In the GC-risk scoring system I, age, plateletocrit (PCT), carcinoembryonic antigen (CEA), glucose, albumin, creatinine were independent risk factors of GC, with scores ranging from 0 to 28 and optimal cut-off was 15.5. The second scoring system consisted of age, PCT, RDW-CV, CEA, glucose, albumin, and creatinine, with scores ranging from 0 to 31. The optimal cut-off point was determined to be 15.5. The scoring system III comprise of age, sex, PCT, RDW CV, CEA, glucose, with scores ranging from 0 to 21 and optimal cut-off was 10.5. All three scoring systems demonstrated excellent discrimination for GC, achieving an AUC of 0.884, 0.89, and 0.876, respectively. In external validation, the AUC values were 0.654, 0.658, and 0.714. Notably, the GC-risk scoring system III exhibited the highest screening efficiency.</p><p><strong>Conclusions: </strong>Urban residents benefited from the effective and verified GC-risk scoring systems, which demonstrated excellent performance in identifying individuals with an elevated risk of GC.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Salivary biomarkers: a promising approach for predicting immunotherapy response in head and neck cancers. 唾液生物标志物:预测头颈部癌症免疫疗法反应的有效方法。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-08 DOI: 10.1007/s12094-024-03742-8
Armin Nejat Dehkordi, Moein Maddahi, Parinaz Vafa, Nasim Ebrahimi, Amir Reza Aref

Head and neck cancers, including cancers of the mouth, throat, voice box, salivary glands, and nose, are a significant global health issue. Radiotherapy and surgery are commonly used treatments. However, due to treatment resistance and disease recurrence, new approaches such as immunotherapy are being explored. Immune checkpoint inhibitors (ICIs) have shown promise, but patient responses vary, necessitating predictive markers to guide appropriate treatment selection. This study investigates the potential of non-invasive biomarkers found in saliva, oral rinses, and tumor-derived exosomes to predict ICI response in head and neck cancer patients. The tumor microenvironment significantly impacts immunotherapy efficacy. Oral biomarkers can provide valuable information on composition, such as immune cell presence and checkpoint expression. Elevated tumor mutation load is also associated with heightened immunogenicity and ICI responsiveness. Furthermore, the oral microbiota may influence treatment outcomes. Current research aims to identify predictive salivary biomarkers. Initial studies indicate that tumor-derived exosomes and miRNAs present in saliva could identify immunosuppressive pathways and predict ICI response. While tissue-based markers like PD-L1 have limitations, combining multiple oral fluid biomarkers could create a robust panel to guide treatment decisions and advance personalized immunotherapy for head and neck cancer patients.

头颈部癌症,包括口腔癌、咽喉癌、声带癌、唾液腺癌和鼻癌,是一个重要的全球性健康问题。放疗和手术是常用的治疗方法。然而,由于耐药性和疾病复发,人们正在探索免疫疗法等新方法。免疫检查点抑制剂(ICIs)已显示出良好的前景,但患者的反应各不相同,因此需要预测性标志物来指导适当的治疗选择。本研究调查了唾液、口腔冲洗液和肿瘤衍生外泌体中发现的非侵入性生物标记物预测头颈癌患者对 ICI 反应的潜力。肿瘤微环境对免疫疗法的疗效有重大影响。口腔生物标记物可以提供有关免疫细胞存在和检查点表达等组成的宝贵信息。肿瘤突变负荷升高也与免疫原性和 ICI 反应性增强有关。此外,口腔微生物群可能会影响治疗效果。目前的研究旨在确定预测性唾液生物标志物。初步研究表明,唾液中的肿瘤外泌体和 miRNA 可识别免疫抑制通路并预测 ICI 反应。虽然 PD-L1 等基于组织的标记物有其局限性,但将多种口腔液生物标记物结合在一起可以创建一个强大的面板,指导头颈部癌症患者的治疗决策并推进个性化免疫疗法。
{"title":"Salivary biomarkers: a promising approach for predicting immunotherapy response in head and neck cancers.","authors":"Armin Nejat Dehkordi, Moein Maddahi, Parinaz Vafa, Nasim Ebrahimi, Amir Reza Aref","doi":"10.1007/s12094-024-03742-8","DOIUrl":"https://doi.org/10.1007/s12094-024-03742-8","url":null,"abstract":"<p><p>Head and neck cancers, including cancers of the mouth, throat, voice box, salivary glands, and nose, are a significant global health issue. Radiotherapy and surgery are commonly used treatments. However, due to treatment resistance and disease recurrence, new approaches such as immunotherapy are being explored. Immune checkpoint inhibitors (ICIs) have shown promise, but patient responses vary, necessitating predictive markers to guide appropriate treatment selection. This study investigates the potential of non-invasive biomarkers found in saliva, oral rinses, and tumor-derived exosomes to predict ICI response in head and neck cancer patients. The tumor microenvironment significantly impacts immunotherapy efficacy. Oral biomarkers can provide valuable information on composition, such as immune cell presence and checkpoint expression. Elevated tumor mutation load is also associated with heightened immunogenicity and ICI responsiveness. Furthermore, the oral microbiota may influence treatment outcomes. Current research aims to identify predictive salivary biomarkers. Initial studies indicate that tumor-derived exosomes and miRNAs present in saliva could identify immunosuppressive pathways and predict ICI response. While tissue-based markers like PD-L1 have limitations, combining multiple oral fluid biomarkers could create a robust panel to guide treatment decisions and advance personalized immunotherapy for head and neck cancer patients.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical & Translational Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1